{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TENIVAC&page=2", "query": { "intervention": "TENIVAC", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TENIVAC&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-15T10:41:26.450Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00109330", "title": "A Combined Tdap Vaccine Used As A Booster Compared To Licensed Td Vaccine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diphtheria", "Tetanus", "Acellular Pertussis" ], "interventions": [ { "name": "Combined diphtheria, tetanus, acellular pertussis vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "10 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "10 Years to 18 Years" }, "enrollment_count": 4116, "start_date": "2002-11", "completion_date": "2004-04", "has_results": false, "last_update_posted_date": "2016-09-09", "last_synced_at": "2026-09-15T10:41:26.450Z", "location_count": 44, "location_summary": "Mesa, Arizona • Tempe, Arizona • Jonesboro, Arkansas + 39 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Escondido", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00109330" }, { "nct_id": "NCT00393276", "title": "Determining Responses to Two Different Vaccines in HIV and HCV Infected Individuals", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections", "Hepatitis C" ], "interventions": [ { "name": "Twinrix", "type": "BIOLOGICAL" }, { "name": "Decavac", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 29, "start_date": "2007-08", "completion_date": "2009-07", "has_results": false, "last_update_posted_date": "2021-11-01", "last_synced_at": "2026-09-15T10:41:26.450Z", "location_count": 11, "location_summary": "San Diego, California • San Francisco, California • Aurora, Colorado + 7 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00393276" }, { "nct_id": "NCT00835237", "title": "Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Tetanus", "Acellular Pertussis", "Diphtheria", "Diphtheria-Tetanus-acellular Pertussis Vaccines" ], "interventions": [ { "name": "Boostrix®", "type": "BIOLOGICAL" }, { "name": "Decavac™", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 1332, "start_date": "2009-02-17", "completion_date": "2009-10-15", "has_results": true, "last_update_posted_date": "2020-01-03", "last_synced_at": "2026-09-15T10:41:26.450Z", "location_count": 24, "location_summary": "Tucson, Arizona • Los Angeles, California • DeLand, Florida + 21 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "DeLand", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Stockbridge", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00835237" }, { "nct_id": "NCT00802867", "title": "Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diphtheria", "Tetanus", "Pertussis", "Polio", "Haemophilus Infection" ], "interventions": [ { "name": "Diphtheria and Tetanus Toxoids and Acellular Pertussis (DAPTACEL®)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sanofi Pasteur, a Sanofi Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "4 Years", "maximum_age": "6 Years", "sex": "ALL", "summary": "4 Years to 6 Years" }, "enrollment_count": 989, "start_date": "2004-02", "completion_date": "2005-09", "has_results": true, "last_update_posted_date": "2016-04-14", "last_synced_at": "2026-09-15T10:41:26.450Z", "location_count": 19, "location_summary": "Jonesboro, Arkansas • Little Rock, Arkansas • Oakland, California + 16 more", "locations": [ { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Oakland", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00802867" }, { "nct_id": "NCT00006066", "title": "Interleukin-2 Plus Anti-HIV Therapy in HIV-Infected Children With Weakened Immune Systems", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed", "type": "BIOLOGICAL" }, { "name": "Diphtheria and Tetanus Toxoids Adsorbed", "type": "BIOLOGICAL" }, { "name": "Tetanus and Diphtheria Toxoids Adsorbed", "type": "BIOLOGICAL" }, { "name": "Bacteriophage phi X 174", "type": "DRUG" }, { "name": "Aldesleukin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "2 Years to 18 Years" }, "enrollment_count": 92, "start_date": null, "completion_date": "2006-06", "has_results": false, "last_update_posted_date": "2021-11-01", "last_synced_at": "2026-09-15T10:41:26.450Z", "location_count": 13, "location_summary": "Long Beach, California • Los Angeles, California • San Diego, California + 8 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006066" }, { "nct_id": "NCT00662870", "title": "Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended Vaccine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diphtheria", "Tetanus", "Whooping Cough", "Polio", "Haemophilus Influenzae Type b" ], "interventions": [ { "name": "DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine)", "type": "BIOLOGICAL" }, { "name": "Pentacel: DTaP-IPV/Hib", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "42 Days", "maximum_age": "84 Days", "sex": "ALL", "summary": "42 Days to 84 Days" }, "enrollment_count": 1941, "start_date": "2001-05", "completion_date": "2004-01", "has_results": false, "last_update_posted_date": "2012-01-31", "last_synced_at": "2026-09-15T10:41:26.450Z", "location_count": 26, "location_summary": "Fayetteville, AR 72703, Arkansas • Jonesboro, AR 72401, Arkansas • Little Rock, AR 72211, Arkansas + 23 more", "locations": [ { "city": "Fayetteville, AR 72703", "state": "Arkansas" }, { "city": "Jonesboro, AR 72401", "state": "Arkansas" }, { "city": "Little Rock, AR 72211", "state": "Arkansas" }, { "city": "Fountain Valley, CA 92708", "state": "California" }, { "city": "Englewood, CO 80112", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00662870" }, { "nct_id": "NCT05096481", "title": "PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "High Grade Glioma", "Diffuse Intrinsic Pontine Glioma", "Recurrent Medulloblastoma" ], "interventions": [ { "name": "PEP-CMV", "type": "BIOLOGICAL" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Tetanus Diphtheria Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Nationwide Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "3 Years to 39 Years" }, "enrollment_count": 120, "start_date": "2024-07-18", "completion_date": "2030-06-15", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-09-15T10:41:26.450Z", "location_count": 13, "location_summary": "Aurora, Colorado • Washington D.C., District of Columbia • Miami, Florida + 10 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05096481" }, { "nct_id": "NCT05609994", "title": "ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Low Grade Glioma of Brain" ], "interventions": [ { "name": "PEPIDH1M vaccine + vorasidenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Katy Peters, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2025-07-15", "completion_date": "2029-08", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-09-15T10:41:26.450Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05609994" }, { "nct_id": "NCT03589768", "title": "Study on the Safety and Immunogenicity of Boostrix Vaccine in Pregnant Malian Women and Their Infants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clostridium Difficile Immunisation", "Diphtheria", "Diphtheria Immunisation", "Pertussis", "Tetanus", "Tetanus Immunisation" ], "interventions": [ { "name": "Tetanus and Diphtheria Toxoids Adsorbed", "type": "BIOLOGICAL" }, { "name": "Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed onto aluminum hydroxide", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "39 Years", "sex": "FEMALE", "summary": "18 Years to 39 Years · Female only" }, "enrollment_count": 399, "start_date": "2019-01-24", "completion_date": "2020-07-01", "has_results": true, "last_update_posted_date": "2025-05-21", "last_synced_at": "2026-09-15T10:41:26.450Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03589768" }, { "nct_id": "NCT00297856", "title": "Post-marketing Safety Study of GSK Biologicals' Boostrix® Vaccine", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Diphtheria", "Tetanus", "Acellular Pertussis" ], "interventions": [ { "name": "Boostrix®", "type": "BIOLOGICAL" }, { "name": "Td (Tetanus diphtheria) vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "10 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "10 Years to 18 Years" }, "enrollment_count": 10000, "start_date": "2006-03", "completion_date": "2006-12", "has_results": false, "last_update_posted_date": "2014-01-13", "last_synced_at": "2026-09-15T10:41:26.450Z", "location_count": 1, "location_summary": "Oakland, California", "locations": [ { "city": "Oakland", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00297856" } ] }